Based on the sole PD-L1 expression, it could be presumed that in PD-L1-positive tumor nivolumab alone should be enough and in PD-L1-negative tumors the combination with ipilimumab could restore the sensitivity to nivolumab. The gene discussed is CD274; the disease is neoplasm.